Clinical Trials Directory

Trials / Completed

CompletedNCT04590079

Innovative Device for Pain Management by Millimeter Band Radiation : Electronic-Pain Killer.

Innovative Device for Pain Management by Millimeter Band Radiation : Electronic-Pain Killer. Evaluation in Patients With Peripheral Osteoarthritis: A Single Center, Prospective, Randomized in Cross-over, Comparative and Open-label Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
University Hospital, Grenoble · Academic / Other
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

In this study, in addition of conventional treatment, the efficacy of the medical device, Remedee One, in medical care of patients with peripheral osteoarthritis pain is evaluated.

Detailed description

Osteoarthritis affects 10 millions people in France (17% of the population). It's the second cause of disability and consultation after the cardiovascular diseases in France. For the moment, there is no curative treatment for osteoarthritis The main clinical sign of this disease is pain and care is based on the treatment of pain and on the improvement of functionnal disability. The proposed treatments are mainly based on the use of oral analgesics treatments . At present, patients report to be insufficiently relieved. New strategies need to be developed. The hypothesis is that the use of an innovative medical device, Remedee One, can reduce the pain felt by patients, improve their quality of life and reduce the analgesics consumption. The choice is oriented on the peripheral osteoarthritis and excludes spinal osteoarthritis because it's an osteoarthritis always asymptomatic and painless.

Conditions

Interventions

TypeNameDescription
DEVICEConventional pain treatment with daily sessions with innovative medical device, Remedee One, for pain management by Millimeter Band RadiationConventional pain treatement with daily sessions with innovative medical device for pain management (radiation in millimeter band) at the rate of 1 to 3 sessions by day of 40 minutes for 3 months.

Timeline

Start date
2020-12-14
Primary completion
2022-08-24
Completion
2022-08-24
First posted
2020-10-19
Last updated
2023-02-14

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04590079. Inclusion in this directory is not an endorsement.